One Health drugs against parasitic vector borne diseases in Europe and beyond (OneHealthdrugs)
OneHealthdrugs aims to coordinate the discovery of drugs that stop vector-borne infections in both human and veterinary settings according to the principles of the optimal profile for both organisms, increasing quality and reducing environmental impact.
OneHealthdrugs aims at coordinating the discovery of drugs halting H&A VBD keeping with the principles of optimal profile for both organisms, increasing the quality and delivery technologies. The COST Action is the ideal platform aiming at the integration and generation of synergies among drug R&D experts from the chemical / biological / human / veterinary and earth science within academies, SMEs, industries, governments. The platform encompasses pre-clinical drug discovery, animal studies, and drug delivery. Strategies such as bioinformatics, PROTAC, nanotechnology will be enhanced.
OneHealthdrugs will impact in Europe and in disease-endemic countries. The Action will provide a compounds database and a white chart about the discovery of new drugs for H&A infections. Expected benefits include the transfer of academia-industry and Northern-Southern world knowledge. Conferences, training schools for advanced technologies, and STSMs are planned. Novel communication technologies to disseminate the Action results to a broad audience including scientists, stakeholders, and citizens are planned. Young researchers will be trained on advanced techniques.
COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. The COST ACTIONS help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.
One Health drugs against parasitic vector borne diseases in Europe and beyond
Maria Paola Costi
Anabela Cordeiro da Silva
Maria Cristina Notarsanto
Maria Esposito and Laura Leonardi